Relation between Erectile Dysfunction and Urinary Incontinence after Nerve-Sparing and Non-Nerve-Sparing Radical Prostatectomy

2004 ◽  
Vol 73 (1) ◽  
pp. 31-35 ◽  
Author(s):  
Akira Tsujimura ◽  
Kiyomi Matsumiya ◽  
Yasushi Miyagawa ◽  
Natsuki Takaha ◽  
Kazuo Nishimura ◽  
...  
Keyword(s):  
Urinary Incontinence ◽  
Erectile Dysfunction ◽  
Radical Prostatectomy ◽  
Nerve Sparing

Inhibition of Interleukin‐6 Attenuates Erectile Dysfunction in a Rat Model of Nerve-Sparing Radical Prostatectomy

2011 ◽  
Vol 8 (7) ◽  
pp. 1957-1964 ◽  
Author(s):  
Shinichi Yamashita ◽  
Ryuichi Kato ◽  
Ko Kobayashi ◽  
Shin‐ichi Hisasue ◽  
Yoichi Arai ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Radical Prostatectomy ◽  
Rat Model ◽  
Interleukin 6 ◽  
Nerve Sparing

scholarly journals MP26-06 NON-HUMAN PRIMATE (NHP) MODEL OF URINARY INCONTINENCE AND ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Joao Zambon ◽  
Manish Patel ◽  
Ashok Hemal ◽  
Gopal Badlani ◽  
Ashley Dean ◽  
...  
Keyword(s):  
Urinary Incontinence ◽  
Erectile Dysfunction ◽  
Radical Prostatectomy ◽  
Human Primate

scholarly journals Detrusorrhaphy during Robot-Assisted Radical Prostatectomy: Early Recovery of Urinary Continence and Surgical Technique

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Tae Young Shin ◽  
Yong Seong Lee
Keyword(s):  
Urinary Incontinence ◽  
Radical Prostatectomy ◽  
Intraoperative Complications ◽  
Risk Groups ◽  
Catheter Removal ◽  
Urinary Continence ◽  
Nerve Sparing ◽  
Robot Assisted ◽  
Early Recovery ◽  
Open Radical Prostatectomy

Robot-assisted radical prostatectomy (RARP) has largely replaced open radical prostatectomy as the standard surgical treatment for prostate cancer. However, postoperative urinary incontinence still persists and has a significant impact on quality of life. We report the superior results of the detrusorrhaphy technique during RARP that helps achieve early continence. Our prospective study involved 95 consecutive patients who underwent RARP between March 2015 and May 2017; fifty patients underwent RARP using the new detrusorrhaphy technique (group 1) and 45 underwent standard RARP (group 2). The postoperative oncological and functional outcomes were compared between the two groups. The postoperative continence was assessed at 0 day, 1 week, 4 weeks, 8–12 weeks, and 6 months after catheter removal. Continence was defined as the use of no pad over a 24 h period. Mean operative time in groups 1 and 2 were 250 and 220 min, respectively. Intraoperative complications were not encountered in any patient. The continence rates after catheter removal in groups 1 and 2 were 68% and 0% at 0 day, 78% and 17.8% at 1 week, 86% and 64.4% at 4 weeks, 92% and 73.3% at 8–12 weeks, and 100% and 91.1% at 6 months, respectively. In the multivariate analysis, the nerve sparing technique, D’Amico risk groups, and prostate volume were involved in the early recovery of urinary continence. The detrusorrhaphy technique is simple, safe, and feasible, which helped achieve earlier continence. It showed significantly better outcomes than those achieved with the standard RARP technique in terms of urinary incontinence. Nevertheless, our findings need to be validated in further studies.

Persistent Erectile Dysfunction Following Radical Prostatectomy: The Association between Nerve-Sparing Status and the Prevalence and Chronology of Venous Leak

2009 ◽  
Vol 6 (10) ◽  
pp. 2813-2819 ◽  
Author(s):  
Raanan Tal ◽  
Rolando Valenzuela ◽  
Nadid Aviv ◽  
Marilyn Parker ◽  
W. Bedford Waters ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Radical Prostatectomy ◽  
Nerve Sparing

1125 A NOVEL TOOL FOR THE PREDICTION OF URINARY INCONTINENCE AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Firas Abdollah ◽  
Alberto Briganti ◽  
Nazareno Suardi ◽  
Andrea Gallina ◽  
Dario Di Trapani ◽  
...  
Keyword(s):  
Urinary Incontinence ◽  
Radical Prostatectomy ◽  
Nerve Sparing

Do we need the nerve sparing radical prostatectomy techniques (intrafascial vs. interfascial) in men with erectile dysfunction? Results of a single-centre study

2014 ◽  
Vol 33 (3) ◽  
pp. 301-307 ◽  
Author(s):  
Wael Y. Khoder ◽  
Raphaela Waidelich ◽  
Michael Seitz ◽  
Armin J. Becker ◽  
Alexander Buchner ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Radical Prostatectomy ◽  
Nerve Sparing ◽  
Single Centre ◽  
Centre Study ◽  
Single Centre Study

Topical alprostadil (Vitaros©) in the treatment of erectile dysfunction after non-nerve-sparing robot-assisted radical prostatectomy

2017 ◽  
Vol 85 (2) ◽  
pp. 55-59 ◽  
Author(s):  
Pier Andrea Della Camera ◽  
Simone Morselli ◽  
Gianmartin Cito ◽  
Giovanni Tasso ◽  
Nicola Laruccia ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Radical Prostatectomy ◽  
Sexual Intercourse ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Nerve Sparing ◽  
Robot Assisted ◽  
Ecog Performance Status ◽  
Comorbidity Index

Objective: The aim of the study is the evaluation of the efficacy and safety of the treatment with topical alprostadil (Vitaros©) in post-robot assisted radical prostatectomy (RARP) rehabilitation therapy of patients with erectile dysfunction (ED). Methods: Seventy-four patients were enrolled and underwent non-nerve-sparing RARP. Inclusion criteria: age <75, preoperatively International Index of Erectile Function (IIEF-5) >16, erection hardness score (EHS) ⩾2, weekly sexual intercourse ⩾1, affirmative answers to Sexual Encounter Profile Question (SEP-Q) 2 and SEP-Q3, Charlson Comorbidity Index (CCI) ⩽5, Eastern Cooperative Oncology Group (ECOG) performance status ⩽1, no moderate/severe cardiovascular disease. Results: Vitaros was administered ⩾2 twice a week. At month 6, the IIEF-5 decreased from 20.5 preoperative to 18.1 post-treatment. EHS score decreased from a mean of 3.3 to a mean of 3.0. The quality of life score decreased from an average of 5.1 to 2.3. Weekly sexual intercourse decreased from an average of 2.1 to 1.7. Six patients dropped out; 89.7% patients showed a positive SEP-Q2 and 77.8% a positive SEP-Q3. All patients responded positively to Global Assessment Questions (GAQ)-1 and 97% to GAQ-2. Of all 68 analyzed patients, 13 (17.6%) switched to intracavernous injection therapy. Conclusions: In conclusion, Vitaros may become a viable alternative to common injective therapies in well-selected patients after RARP.

Sign in / Sign up

Export Citation Format

Share Document